Guidelines for the Quality Control of Population Pharmacokinetic-Pharmacodynamic Analyses: an Industry Perspective

被引:26
|
作者
Bonate, P. L. [1 ]
Strougo, A. [2 ]
Desai, A. [1 ]
Roy, M. [1 ]
Yassen, A. [2 ]
van der Walt, J. S. [2 ]
Kaibara, A. [3 ]
Tannenbaum, S. [1 ]
机构
[1] Astellas Pharma Global Dev, Northbrook, IL 60062 USA
[2] Astellas Pharma Global Dev, NL-2353W Leiderdorp, Netherlands
[3] Astellas Pharma Inc, Itabashi Ku, Tokyo 1748612, Japan
来源
AAPS JOURNAL | 2012年 / 14卷 / 04期
关键词
modeling; NONMEM; quality assurance; VALIDATION; MODEL;
D O I
10.1208/s12248-012-9387-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quality population modeling and simulation analyses and reports are something every modeler desires. However, little attention in the literature has been paid to what constitutes quality regarding population analyses. Very rarely do published manuscripts contain any statement about quality assurance of the modeling results contained therein. The purpose of this manuscript is to present guidelines for the quality assurance of population analyses, particularly with regards to the use of NONMEM from an industrial perspective. Quality guidelines are developed for the NONMEM installation itself, NONMEM data sets, control streams, output listings, output data files and resultant post-processing, reporting of results, and the review processes. These guidelines were developed to be thorough yet practical, though are not meant to be completely comprehensive. It is our desire to ensure that what is reported accurately reflects the collected data, the modeling process, and model outputs for a modeling project.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 50 条
  • [21] Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments
    Andrew Hooker
    Paolo Vicini
    The AAPS Journal, 7
  • [22] Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process - Experience at Parke-Davis
    Olson, SC
    Bockbrader, H
    Boyd, RA
    Cook, J
    Koup, JR
    Lalonde, RL
    Siedlik, PH
    Powell, JR
    CLINICAL PHARMACOKINETICS, 2000, 38 (05) : 449 - 459
  • [23] In Silico Assessment of Nifedipine Effects on Human Heart Cells: Pharmacokinetic-Pharmacodynamic Analyses at the Population Level
    Abbasi, Mitra
    Polak, Sebastian
    2017 COMPUTING IN CARDIOLOGY (CINC), 2017, 44
  • [24] Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
    Kloprogge, Frank
    Mwandumba, Henry C.
    Banda, Gertrude
    Kamdolozi, Mercy
    Shani, Doris
    Corbett, Elizabeth L.
    Kontogianni, Nadia
    Ward, Steve
    Khoo, Saye H.
    Davies, Geraint R.
    Sloan, Derek J.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (07):
  • [25] Current clinical use of reteplase for thrombolysis - A pharmacokinetic-pharmacodynamic perspective
    Martin, U
    Kaufmann, B
    Neugebauer, G
    CLINICAL PHARMACOKINETICS, 1999, 36 (04) : 265 - 276
  • [26] Current Clinical Use of Reteplase for ThrombolysisA Pharmacokinetic-Pharmacodynamic Perspective
    Ulrich Martin
    Burchard Kaufmann
    Günter Neugebauer
    Clinical Pharmacokinetics, 1999, 36 : 265 - 276
  • [27] Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation
    Saito, Tomohisa
    Iida, Satofumi
    Terao, Kimio
    Kumagai, Yuji
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (12): : 1564 - 1572
  • [28] An interactive pharmacokinetic-pharmacodynamic model for patientspecific HIV treatment guidelines.
    Gajendran, V.
    Kahn, J.
    Mehta, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S145 - S145
  • [29] Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
    van Hasselt, J. G. C.
    Boekhout, A. H.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) : 126 - 132
  • [30] Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib
    Dunn, Allison
    Ditmarsch, Marc
    Kastelein, John J. P.
    Kling, Douglas
    Neild, Annie
    Davidson, Michael H.
    Gobburu, Joga
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (09): : 1150 - 1164